Literature DB >> 4029081

[3H]cortivazol: a unique high affinity ligand for the glucocorticoid receptor.

J A Schlechte, S S Simons, D A Lewis, E B Thompson.   

Abstract

Cortivazol (CVZ) and deacylcortivazol (DAC) are pyrazolosteroids with potent glucocorticoid activity. In previous work we showed that DAC is 40-fold more potent than dexamethasone (DEX) in lysing leukemic lymphoblasts. To assess the interaction between these atypical steroids and the glucocorticoid receptor, we examined the binding of [3H]CVZ to cytosol from glucocorticoid-sensitive and -resistant variants of the human leukemic cell line CEM C7. In glucocorticoid-sensitive cells [3H]CVZ causes a 2-fold induction of glutamine synthetase and binds to a protein in the 4.6 S region of high salt sucrose gradients. On DEAE-cellulose chromatography, [3H]CVZ-receptor complexes show a shift from high (0.25 M KP) to low salt (0.09 M KP) eluting forms upon activation. CVZ competes for a 97,000-dalton protein labeled by [3H]dexamethasone mesylate. Scatchard analysis of the binding of [3H]CVZ in glucocorticoid-sensitive cells revealed a curvilinear plot which resolved into high (0.4 nM) and low (11 nM) affinity components. The receptor concentration of the low affinity site (0.30 pmol/mg protein) was approximately twice that of the high affinity site (0.14 pmol/mg protein). Dissociation experiments with dilution and/or excess unlabeled CVZ supported the presence of independent sites. In contrast, the binding of [3H]DEX to C7 cytosol revealed a single class of binding sites (Kd = 1.9 nM; receptor concentration, 0.46 pmol/mg protein). Examination of the binding of [3H]CVZ using 10(-5) M DEX as the competing ligand showed that DEX binds only to the low affinity site detected by [3H]CVZ. In cytosol from a glucocorticoid-resistant cell line with virtually no [3H]DEX binding, [3H]CVZ detected a single high affinity binding site that was similar in dissociation constant (0.8 nM) and receptor concentration (0.13 pmol/mg protein) to the high affinity site detected in the glucocorticoid-sensitive cell line C7.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029081     DOI: 10.1210/endo-117-4-1355

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

Review 1.  Corticosteroid receptor antagonists: a current perspective.

Authors:  W Sutanto; E R de Kloet
Journal:  Pharm World Sci       Date:  1995-03-24

2.  Deacylcortivazol-like pyrazole regioisomers reveal a more accommodating expanded binding pocket for the glucocorticoid receptor.

Authors:  Jessica A O Zimmerman; Mimi Fang; Bintou Doumbia; Alexis Neyman; Ji Hyeon Cha; Michael Thomas; Bonnie Hall; Meng Wu; Anne M Wilson; Miles A Pufall
Journal:  RSC Med Chem       Date:  2020-12-08

3.  Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol.

Authors:  Kelly Suino-Powell; Yong Xu; Chenghai Zhang; Yong-Guang Tao; W David Tolbert; S Stoney Simons; H Eric Xu
Journal:  Mol Cell Biol       Date:  2007-12-26       Impact factor: 4.272

4.  Structural Analysis on the Pathologic Mutant Glucocorticoid Receptor Ligand-Binding Domains.

Authors:  Darrell E Hurt; Shigeru Suzuki; Takafumi Mayama; Evangelia Charmandari; Tomoshige Kino
Journal:  Mol Endocrinol       Date:  2016-01-08

5.  A screening assay for Selective Dimerizing Glucocorticoid Receptor Agonists and Modulators (SEDIGRAM) that are effective against acute inflammation.

Authors:  Jolien Souffriau; Melanie Eggermont; Sara Van Ryckeghem; Kelly Van Looveren; Lise Van Wyngene; Evelien Van Hamme; Marnik Vuylsteke; Rudi Beyaert; Karolien De Bosscher; Claude Libert
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.